ulixertinib + hydroxychloroquine

Ulixertinib + hydroxychloroquine is an investigational combination of two small molecule drugs: ulixertinib, a reversible and highly potent ERK1/2 kinase inhibitor targeting the MAPK/ERK pathway, and hydroxychloroquine, an antimalarial and immunomodulatory agent. Ulixertinib inhibits ERK1 and ERK2 kinases, preventing tumor cell proliferation and survival driven by MAPK pathway activation, especially in cancers with BRAF, NRAS, or KRAS mutations[1][3][7]. Hydroxychloroquine works by inhibiting lysosomal acidification, reducing autophagy, and dampening immune activation[6]. The rationale for the combination centers on ulixertinib suppressing oncogenic signaling while hydroxychloroquine impairs autophagy, which is often upregulated in tumor survival—especially when targeted therapies are used. The combination is under investigation for advanced solid tumors, with evidence of synergistic antitumor effects in preclinical models[1][5].

Brand names

Sovuna

Other names

ulixertinibhydroxychloroquine